Abstract
Allergic contact dermatitis is a common disease within the family of delayed-type hypersensitivity reactions. In more severe cases of allergic contact dermatitis, topical steroids may prove insufficient, and systemic therapeutic agents are often used. Even when systemic therapies such as cyclosporine lead to improvement, withdrawal of these agents is challenging and can lead to undesirable morbidities. Currently, there are no systemic treatments indicated for the treatment of widespread recalcitrant contact dermatitis. This review discusses the targets of in-use off-label systemic medications and potential therapeutics in the pipeline.
MeSH terms
-
Adalimumab / therapeutic use
-
Adrenal Cortex Hormones / therapeutic use
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Azathioprine / therapeutic use
-
Cyclosporine / therapeutic use
-
Dermatitis, Allergic Contact / drug therapy*
-
Etanercept / therapeutic use
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Infliximab / therapeutic use
-
Methotrexate / therapeutic use
-
Mycophenolic Acid / therapeutic use
-
Off-Label Use
-
Thalidomide / analogs & derivatives
-
Thalidomide / therapeutic use
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Adrenal Cortex Hormones
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunosuppressive Agents
-
Tumor Necrosis Factor-alpha
-
dupilumab
-
Thalidomide
-
Cyclosporine
-
Infliximab
-
Adalimumab
-
Mycophenolic Acid
-
Azathioprine
-
Etanercept
-
apremilast
-
Methotrexate